Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Regeneron antibody cocktail wins emergency use authorization

By Brian Buntz | November 24, 2020

Regeneron Pharmaceuticals (NSDQ:REGN) has announced that the FDA has granted emergency use authorization (EUA) for the combination of casirivimab and imdevimab to treat COVID-19. 

The monoclonal antibody cocktail is reportedly the first treatment to show “statistically significant anti-viral activity” against COVID-19, according to its developer. In a trial, the combination of drugs cut hospitalization or emergency room visits for high-risk patients compared to placebo. 

FDA has cleared the way for the monoclonal antibodies to be used for newly diagnosed SARS-COV-2 cases in high-risk patients. 

The drug is not authorized for COVID-19 patients who are hospitalized or on oxygen therapy.

President Trump received the drug when hospitalized with COVID-19 in October. 

The U.S. government will clear the way for some 300,000 patients to receive the drug cocktail at no charge under a U.S. government allocation program.  

To qualify as “high risk” and thus be eligible for the drug, patients need to be either obese, over 65 or have a specified chronic disease (chronic kidney disease, diabetes or immunosuppressive disease). Patients over the age of 55 are also eligible if they have cardiovascular disease, hypertension or a chronic respiratory disease. Adolescents also qualify for the therapy under certain conditions.  

Casirivimab and imdevimab are administered intravenously.

To date, more than 12.3 million people in the U.S. have been diagnosed with COVID-19, according to Johns Hopkins University.

In October, FDA approved Regeneron’s Inmazep, a mixture of three monoclonal antibodies, to treat Ebola. 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
Johnson & Johnson vaccine trial results expected soon
OncoSec eyes next steps with its cancer immunotherapy candidate
Pharma researcher charged with theft of trade secrets  
Norway investigating deaths of 23 individuals who received COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards